SRRK
Scholar Rock Holding Corp
NASDAQ · Healthcare · Biotechnology · US
$46.65
−4.83%Sep 14, 2026, 12:38 UTC
Scholar Rock set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy directly targeting muscle loss in patients with the rare genetic disorder.
Source:Sep 11, 2026, 21:27 UTC
The U.S. Food and Drug Administration approved Scholar Rock's therapy for a rare genetic condition that causes muscle weakness.
Aug 17, 2026, 23:04 UTC
Scholar Rock resubmitted a biologics license application for apitegromab, its SMA treatment, supported by an alternate fill-finish manufacturing facility, with an FDA decision date of September 30.
Source:Aug 7, 2026, 13:05 UTC
Scholar Rock resubmitted its biologics license application for apitegromab, with a FDA decision expected by September 30.
Aug 6, 2026, 00:00 UTC
Scholar Rock Holding Corp reported its Q2 2026 financial results, with zero revenue and a net loss of $109.9 million, or $0.84 per diluted share.
Source: